These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12584035)

  • 1. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.
    Smith SY; Recker RR; Hannan M; Müller R; Bauss F
    Bone; 2003 Jan; 32(1):45-55. PubMed ID: 12584035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey.
    Müller R; Hannan M; Smith SY; Bauss F
    J Bone Miner Res; 2004 Nov; 19(11):1787-96. PubMed ID: 15476578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
    Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
    Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.
    Bauss F; Lalla S; Endele R; Hothorn LA
    J Rheumatol; 2002 Oct; 29(10):2200-8. PubMed ID: 12375334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
    Mori H; Tanaka M; Kayasuga R; Masuda T; Ochi Y; Yamada H; Kishikawa K; Ito M; Nakamura T
    Bone; 2008 Nov; 43(5):840-8. PubMed ID: 18718565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
    Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
    Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey.
    Smith SY; Jolette J; Chouinard L; Komm BS
    J Bone Miner Metab; 2015 Mar; 33(2):161-72. PubMed ID: 24633538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minodronic acid ameliorates vertebral bone strength by increasing bone mineral density in 9-month treatment of ovariectomized cynomolgus monkeys.
    Tanaka M; Mori H; Kawabata K; Mashiba T
    Bone; 2016 Jul; 88():157-164. PubMed ID: 27155564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats.
    Sakai S; Takeda S; Sugimoto M; Shimizu M; Shimonaka Y; Yogo K; Hashimoto J; Bauss F; Endo K
    Bone; 2015 Dec; 81():449-458. PubMed ID: 26281770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral weekly ibandronate prevents bone loss in postmenopausal women.
    Tankó LB; Felsenberg D; Czerwiński E; Burdeska A; Jonkanski I; Hughes C; Christiansen C;
    J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.
    Kurth AH; Eberhardt C; Müller S; Steinacker M; Schwarz M; Bauss F
    Bone; 2005 Aug; 37(2):204-10. PubMed ID: 15936997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
    Schlosser K; Scigalla P
    Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
    Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
    Bauss F; Russell RG
    Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid.
    Glatt M; Pataki A; Evans GP; Hornby SB; Green JR
    Osteoporos Int; 2004 Sep; 15(9):707-15. PubMed ID: 15024556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.